{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:40:23Z","timestamp":1790008823842,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T00:00:00Z","timestamp":1206316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>mTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>C4\u20102 CaP cells were injected into tibiae of mice and the animals were treated with RAD001, docetaxel, and zoledronic acid alone or in combination. Histomorphometrical analysis, serum PSA measurements, bone mineral density (BMD), and \u00b5CT were used to determine the effects of treatment on tumor and bone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three\u2010drug treatment showed the greatest effect: 64% inhibition versus control (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Treatment with RAD001 interfered with the weight loss associated with growth of this tumor in the bone (non\u2010RAD001 groups: 4.0% decrease in body weight, <jats:italic>P<\/jats:italic>\u2009=\u20090.0014; RAD001 groups: increase of 3.6% in body weight, <jats:italic>P<\/jats:italic>\u2009=\u20090.0037).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RAD001 inhibited growth of C4\u20102 cells in bone, an effect augmented by addition of docetaxel and zoledronic acid. Moreover RAD001 had a significant impact on maintenance of body weight. RAD001 may hold promise for its effects on both metastatic CaP and the important syndrome of tumor cachexia. Prostate 68:861\u2013871, 2008. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.20752","type":"journal-article","created":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T17:16:29Z","timestamp":1206378989000},"page":"861-871","source":"Crossref","is-referenced-by-count":53,"title":["RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid"],"prefix":"10.1002","volume":"68","author":[{"given":"Todd M.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.M.","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted S.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Poliachik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Vessella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi113"},{"key":"e_1_2_1_3_2","first-page":"2720","article-title":"Frequent inactivation of PTEN in prostate cancer cell lines and xenografts","volume":"58","author":"Vlietstra RJ","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650091003"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2004.01.009"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-1004-6"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10311"},{"key":"e_1_2_1_8_2","first-page":"145","article-title":"The role of PTEN in the progression and survival of prostate cancer","volume":"28","author":"Deocampo ND","year":"2003","journal-title":"Minerva Endocrinol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00215-0"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3137"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171076798"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400978"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.09.132"},{"key":"e_1_2_1_14_2","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Grunwald V","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000138829.97838.19"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00240-002-0282-1","article-title":"Rapamycin induces Smad activity in prostate cancer cell lines","volume":"30","author":"van der Poel HG","year":"2003","journal-title":"Urol Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000108100.53239.b7"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1612"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1052"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-3554-2"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1986"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735404270757"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","article-title":"Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition","volume":"4","author":"Goudar RK","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_1_26_2","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey E","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500815"},{"key":"e_1_2_1_28_2","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee MV","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2005.n.009"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2002.n.016"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl041"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2033"},{"key":"e_1_2_1_35_2","unstructured":"CoreyE QuinnJE ZhangJ OdmanA BrownLG KellerET VessellaRL.Evaluation of effects of osteoprotegerin and zoledronic acid on C4\u20102 prostate cancer bone metastasis. Third North American Symposium on Skeletal Metastases 2002; Bethesda MD2002."},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.10.1882"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10091"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200408161"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-15"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0025-4"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.2.3588"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1128(200101)21:1<83::AID-MED4>3.0.CO;2-1"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1124147"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.20752","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.20752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T23:57:41Z","timestamp":1700006261000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.20752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,24]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1002\/pros.20752"],"URL":"https:\/\/doi.org\/10.1002\/pros.20752","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,24]]}}}